Free Trial
NASDAQ:ETNB

89BIO Q2 2025 Earnings Report

89BIO logo
$9.02 -0.46 (-4.85%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$9.02 0.00 (0.00%)
As of 08/7/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89BIO EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.22
One Year Ago EPS
-$0.48

89BIO Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89BIO Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Earnings Documents

89BIO Earnings Headlines

89bio (ETNB) Q2 R&D Jumps 131%
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
89BIO (ETNB) to Release Quarterly Earnings on Monday
See More 89BIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89BIO and other key companies, straight to your email.

About 89BIO

89BIO (NASDAQ:ETNB), Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89BIO Profile

More Earnings Resources from MarketBeat